S8442
SU 5416
≥98% (HPLC), powder, neuronal nitric oxide synthase inhibitor
别名:
1,3-二氢-3-[（3,5-二甲基-1H-吡咯-2-基）亚甲基]-2H-吲哚-2-酮
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C15H14N2O
化学文摘社编号:
分子量:
238.28
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
SU 5416, ≥98% (HPLC)
SMILES string
Cc1cc(C)c(C=C2C(=O)Nc3ccccc23)[nH]1
InChI key
WUWDLXZGHZSWQZ-XYOKQWHBSA-N
InChI
1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8+
assay
≥98% (HPLC)
form
powder
color
yellow to yellow-orange
mp
221-222 °C
solubility
DMSO: 20 mg/mL, clear (warmed)
H2O: insoluble
storage temp.
−20°C
Quality Level
Gene Information
human ... EGFR(1956), FLT1(2321), IGFBP1(3484), IL2(3558), KDR(3791), PDGFRB(5159)
mouse ... Flt1(14254), Kdr(16542)
Application
SU 5416已用于在血管形成试验前处理人脐静脉内皮细胞(HUVEC)，评估它对血管形成网络的影响。可诱发小鼠的肺动脉高压(PH)成为实验模型。
Biochem/physiol Actions
SU 516可抑制神经元一氧化氮合酶的活性并保护神经元细胞免受一氧化氮介导的神经毒性的影响。1 它还可作为芳烃受体的激动剂，是治疗自身免疫疾病和移植排斥的有效临床试剂。2
SU 5416是一种血管内皮生长因子（VEGF）受体蛋白酪氨酸激酶1/2抑制剂。
Features and Benefits
该化合物是激酶磷酸酶生物学研究的推荐产品。点击这里 发现更多精选激酶磷酸酶生物学产品。了解更多有关用于其他研究领域的生物活性小分子的信息，请访问 sigma.com/discover-bsm。
General description
SU 5416是一种血管内皮生长因子（VEGF）受体蛋白酪氨酸激酶1/2抑制剂。SU 5416可以抑制肿瘤生长和肿瘤血管新生。SU 5416抑制神经元型一氧化氮合酶活性，保护神经元细胞免遭一氧化氮介导的神经毒性伤害。也用作芳烃受体激动剂，还可能作为临床药物，有效治疗自身免疫疾病和移植排斥。
存储类别
11 - Combustible Solids
wgk
WGK 3
ppe
dust mask type N95 (US), Eyeshields, Gloves
Joshua D Mezrich et al.
PloS one, 7(9), e44547-e44547 (2012-09-13)
The experimental compound SU5416 went as far as Phase III clinical trials as an anticancer agent, putatively because of its activity as a VEGFR-2 inhibitor, but showed poor results. Here, we show that SU5416 is also an aryl hydrocarbon receptor
Loredana Ciuclan et al.
American journal of respiratory and critical care medicine, 184(10), 1171-1182 (2011-08-27)
The complex pathologies associated with severe pulmonary arterial hypertension (PAH) in humans have been a challenge to reproduce in mice due to the subtle phenotype displayed to PAH stimuli. Here we aim to develop a novel murine model of PAH
Hidenori Moriyama et al.
Nature communications, 13(1), 3013-3013 (2022-06-01)
Pulmonary hypertension is a fatal rare disease that causes right heart failure by elevated pulmonary arterial resistance. There is an unmet medical need for the development of therapeutics focusing on the pulmonary vascular remodeling. Bioactive lipids produced by perivascular inflammatory
Yong Liu et al.
Journal of orthopaedic translation, 23, 29-37 (2020-06-02)
Accelerating the process of bone regeneration is of great interest for surgeons and basic scientists alike. Recently, umbilical cord mesenchymal stem cells (UCMSCs) are considered clinically applicable for tissue regeneration due to their noninvasive harvesting and better viability. Nonetheless, the
Xiaowei Nie et al.
Journal of hypertension, 35(12), 2419-2435 (2017-07-14)
Similar to cancer, pulmonary arterial hypertension (PAH) is characterized by vascular remodeling, which leads to obliteration of the small pulmonary arteriole, with marked proliferation of pulmonary artery smooth muscle cells (PASMC) and/or endothelial cells dysfunction. Aberrant expression of tumor suppressor
商品
Discover Bioactive Small Molecules for Kinase Phosphatase Biology
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持